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Abstract 
Oncolytic virus therapy (OV therapy) exploits naturally occurring or genetically 
modified viruses to kill cancer cells by lytic destruction. Cysteine-rich protein 61 (Cyr61) 
has been found to be upregulated by OV infection. Cyr61 was found to inhibit OV 
infection when using a transient transfection model and when using a tetracycline 
inducible Cyr61 expression model. In vivo studies using the tetracycline inducible cell 
lines have shown an inhibition of infection with both subcutaneous and intracranial 
models. Expression was verified in vitro and in vivo using Western blot. Interferon-
induced transmembrane protein 3 (IFITM3) was found to be upregulated in the 
presence of high levels of Cyr61. As IFITM3 has been previously shown to inhibit the 
influenza A virus, filoviruses, SARS coronavirus and the HIV-1 virus, its upregulation was 
posited as the potential mechanism for the observed Cyr61 mediated OV inhibition and 
thus a potential target for the improvement of treatment efficacy. Indeed, IFITM3 
protein was found to be upregulated following OV infection by Western blot in several 
glioma cell lines. In order to test the effect of IFITM3 on infection, U87, Ln229 and 
U251T2 cells transiently transfected with IFITM3 protein were infected with an 
oncolytic herpes simplex virus (HSV-1) harboring a luciferase reporter transgene under 
an immediate early promoter. Viral quantification was performed by quantifying 
luciferase activity, normalized to GAPDH protein concentration. No inhibition of OV 
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infection upon increased IFITM3 levels was noted in any cell line. Therefore, it was 
concluded that IFITM3 is unlikely to be a mediator of OV therapy inhibition or a target 
for treatment efficacy improvement. 
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Chapter 1: Introduction 
Glioblastoma Multiforme (GBM) 
 The most frequently occurring(1) of all brain cancers is glioblastoma 
multiforme, which the World Health Organization designates as a grade IV 
astrocytoma. GBM is marked by the presence of small necrotizing regions surrounded 
by anaplastic cells and is highly motile(2). This motility leads to both local infiltration 
and diffuse spread throughout the brain. Another feature of GBM is a high degree of 
angiogenesis. This angiogenesis feeds tumor growth and is strongly linked to both 
malignancy(2) and the exponential growth phase of tumors. Angiogenesis has also 
been shown to suppress immune system recognition of the tumor(3). Glioblastoma 
may arise de novo or from a preexisting lower grade glioma and is also one of the 
most fatal and refractory cancers, with a median time to progression of six months(1) 
and median standard of care survival of 12-14 months(2).  Current treatments consist 
of a combination of radiation, surgical resection, and chemotherapy. However, these 
treatments just add months to the median survival, and <5% of patients survive 5 
years(2). These mortality statistics have not changed much in 50 years and these 
tumors have resisted(1) innovations in surgery, radiotherapy and chemotherapy. One 
cause of the difficulties in treatment is the high motility of GBM. As it is spread 
throughout the brain, complete surgical resection is impossible and the intact blood 
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brain barrier of healthy regions prevents chemotherapeutic drug access(2). The poor 
prognosis of GBM patients necessitates the development of new therapeutic options. 
Oncolytic Virotherapy (OV Therapy) 
 The idea of treating cancer with viruses is not a new one, as spontaneous tumor 
regression following viral sickness or rabies vaccination was noticed in 1904(1). 
Multiple studies were done in the intervening years, but the most successful might be 
the 1956 National Cancer Institute study(4) where nearly half of patients experienced 
tumor regression after wild-type adenovirus treatment. However, this regression was 
quickly followed by progression, and the investigations were abandoned when a 
survival benefit was not observed. With modern genetic methods of virology, 
oncolytic virotherapy has undergone a recent resurgence. Many clinical trials have 
begun, and recently a Phase III trial(5) demonstrated OV therapy’s efficacy as a 
treatment for squamous cell carcinoma. Gene deletion and modification have 
minimized toxicity by allowing OVs to only replicate in tumor cells(6,7). This has 
permitted many different attenuated viruses to be utilized as OV treatments, and 
arguably the most favored are reoviruses, adenoviruses and herpes simplex virus 
(HSV) -1 (8).  
 HSV-1 is uniquely suited as an OV therapy for brain cancer, as it is non-
integrating, well studied, has room for gene addition, specifically targets neural cells, 
and toxicity can be treated with existing antivirals. Gene addition is particularly 
important, as this allows for greater therapeutic potential. For example, prodrug 
activating genes have been included in oncolytic HSV(9). Oncolytic HSV-1 has also 
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been used in clinical trials which have shown it to be minimally toxic(10) and in animal 
trials which have shown an improvement in survival(11) in a glioblastoma multiforme 
model. This low toxicity arises from two modifications generally made in oncolytic 
HSV that render it avirulent in the CNS but proliferative in neoplastic cells(1). One of 
these modifications has the added benefit of hypersensitizing the virus to treatments 
such as acyclovir(12). Although oncolytic HSV is safe, human clinical trials have not 
been very successful. A few problems have been proposed that might contribute to 
this lack of efficacy. First, viral spread from the initial area of injection is limited, 
which prevents effective treatment. One possible solution to this involves the viral 
production of enzymes degrading the extracellular matrix proteins that inhibit viral 
diffusion. Attenuation of the virus to improve safety has also limited its replicative 
ability and the immune system’s clearance of the virus decreases infection. The 
reintroduction of deleted genes under cancer specific promoters increases viral 
proliferation while still maintaining safety(13).  
Relevance of OV therapy to GBM treatment 
 As current therapies have not improved survival beyond a few additional 
months, a new therapy is essential for survival improvement. OV therapy offers a 
number of benefits over conventional treatments. As a highly targeted treatment, OV 
therapy promises the potential of low toxicity and minimal side effects. Radiation and 
chemotherapy are notorious for their toxic side effects, as both damage normal cells 
as well as tumor cells. Surgical resection, due to the invasive nature of GBM, either 
risks removing healthy tissue and creating deficits or leaving tumor behind and failing 
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to prevent mortality. Another potential benefit of OV therapy is the potential to 
reach cells beyond the main tumor mass. Another potential benefit of OV therapy is 
its ability to provide targeted gene therapy. Anti-angiogenic compounds(11) and 
prodrug converting enzymes(8) have both been included in OV therapy, increasing 
efficacy and survival in animal models. 
Cysteine-rich, Angiogenic Inducer, 61 (Cyr61) and OV Therapy 
 Cyr61 is a human 44 kDa protein found intracellularly and secreted into the 
extracellular matrix. It has been found to be tumorigenic(13) and angiogenic(14). This 
angiogenesis is brought about through αvβ5 integrin activation. Upon OV therapy 
Cyr61 has been found to be upregulated(15), as seen in Figure 1. Unpublished results 
in the Kaur lab have shown that the induction of Cyr61 inhibits oncolytic HSV 
infection, promotes angiogenesis, aids tumor regrowth and also limits oncolytic virus 
efficacy. This process of induction and secretion of Cyr61, which acts to inhibit viral 
infection in nearby cells as seen in Figure 2, offers obvious possibilities as a means for 
mediating a local antiviral response. 
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  Figure 1. Cyr61 upregulated after oncolytic virotherapy. 
Rats with intracranial tumors (D74/HveC glioma cells) were treated with hrR3 7 days 
after tumor implantation. Twenty-four hours after OV treatment, cerebrospinal fluid 
(CSF) and tumors were harvested from the rats. Cyr61 is seen upregulated following 
oncolytic virotherapy treatment in both the CSF and in tumor lysates when compared 
with the PBS treated controls. 
(Adapted from Kurozumi et al. Mol Therapy 2008 Aug; 16(8)). 
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Figure 2. Inhibition of OV Infection by Cyr61 
Gli36 and U251T2 human glioma cells were transiently transfected with Cyr61 plasmid 
or empty vector.  24 hours later they  were infected with at an MOI 1.  Cell lysates 
were harvested for luciferase activity and normalized to mg of total protein. Cells 
harboring the Cyr61 plasmid had a significant reduction in luciferase  activity as 
compared to control. Figure adapted from Haseley A et al. Unpublished. 
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Interferon-Induced Transmembrane protein 3 (IFITM3) 
 Interferons were first discovered 50 years ago when they were induced by 
heat inactivated viral particles(16). They have since been found to coordinate a large 
segment of the innate immune response to viral infection(17). Interferons are 
commonly used to treat viral diseases such as hepatitis C and have been used as an 
adjunct to melanoma therapy (18). 
 IFITM3 has only recently experienced a high level of interest, caused by the 
discovery of its role in viral inhibition. IFITM3 is a 15 kDa human membrane-bound 
protein with 2 transmembrane regions. IFITM3, as the name suggests, can be induced 
by interferon-α and interferon-γ. Interferon-α controls IFITM3’s expression by 
reversible DNA demethylation of its highly regulated core promoter(19). IFITM3, along 
with other interferon inducible proteins, is also known as a member of the fragilis 
gene family. It has been found to play a role in germ cell development and homing(20). 
Beyond the developmental role, however, IFITM3 does play a role in innate 
immunity. 
  IFITM3 has been found to inhibit West Nile virus, dengue virus, H1N1 
influenza, HIV and filoviruses(19, 21). IFITM proteins are believed to be localized to the 
late stage endocytic pathway and inhibit a broad range of enveloped viruses(21). 
Modification by S-palmitoylation controls IFITM3’s membrane clustering and antiviral 
activity against the influenza virus(22). 
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Objectives 
 Cyr61 was identified as a protein of interest due to its effect on angiogenesis and 
its upregulation following OV infection. Preliminary studies implied that Cyr61 
inhibited viral infection, a novel result, so further analysis was performed. The gol of 
this project is to validate OV inhibition by Cyr61 and analyze a potential mechanism 
for it. As IFITM3 was noted in a microarray to be upregulated, and due to its known 
role in the innate immune response to enveloped viruses, IFITM3 was selected for 
further analysis. By identifying mechanisms behind viral inhibition, two benefits are 
accrued: first, one gains a greater understanding of how the body responds to viral 
infection, with possible treatment potential. Second, one can subvert this process to 
increase the efficacy of OV therapy. 
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Figure 3. Proposed mechanism for Cyr61 and IFITM3 mediated inhibition of 
infection 
It was hypothesized that OV infection leads to Cyr61 production and secretion. This in turn 
leads to IFITM3 upregulation and IFITM3 then inhibits further OV infection. 
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Chapter 2: Material and Methods 
Cells, Viruses and Viral Titration 
 Human U251T2, Gli36, U343 and U87 cell lines were maintained in Dulbecco’s 
modified minimal essential medium (DMEM) supplemented with 100µg/mL penicillin, 
100µg/mL streptomycin, and 10% fetal bovine serum (FBS). Gli36 cells were 
maintained in selection with 4 µg/mL blasocidin and 2 µg/mL puromycin, but 
selection was not employed during experimentation. 
 Two HSV-1 derived oncolytic viruses were used: rHSVQ1, and rQ1-α-Fluc. The 
genetic structures of both of these viruses and HSV-1 are provided in Figure 4. 
rHSVQ1 has the gene for the enhanced green fluorescence protein (EGFP) inserted 
within the UL39 locus of ICP6/RR. This inactivation of ribonucleotide reductase limits 
replication to within actively cycling cells. The presence of green fluorescence protein 
(GFP) under the control of the ICP6 locus provides for easy visualization via 
fluorescent microscopy. In addition, both copies of γ34.5, which is responsible for 
HSV1’s neurovirulence and for host protein shutoff, have been deleted. This virus 
thus incorporates two methods of glioma targeting. rQ1-α-Fluc is built upon the same 
backbone as rHSVQ1, but includes the luciferase transgene underneath the HSV-1 
IE4/5 promoter (virus courtesy Tarada et al.23). Viral stocks were generated and 
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maintained in Vero cells, derived from green monkey kidneys (American Type Culture 
Collection, Manassas, VA). 
 Viral particle quantities were assessed using a viral titration protocol. 10,000 
Vero cells are plated per well in a 96 well plate and allowed to adhere overnight. The 
next day, virus stock is sequentially diluted from 10-4 through 10-10. 100µL of each 
dilution are added to each well and infected for 24±1 h at 37˚C. Using a fluorescent 
microscope, wells with at least one cell fluorescing in only green, and thus being 
infected with virus, are marked. The dilution with the nearest to 50% of wells marked 
is chosen as the dilution. Any wells marked in the next lower dilution are attributed 
to pipetting error and are added to the number of positive wells in the chosen 
dilution and divided by the number of wells in the chosen dilution. This percentage is 
then multiplied by 10 and the dilution factor, and the resultant number is the titer in 
the units of plaque forming units/milliliter (pfu/mL). 
 This unit is used to calculate the Multiplicity of Infection (MOI). The 
probability of a cell absorbing n virus particles follows the Poisson distribution, and 
the infectivity differences can be controlled for by using a functional definition of viral 
particles. Plaque forming units (pfu) are therefore ideal for use, as this unit only 
counts the entry of viral particles that can produce GFP and thus are presumed to be 
functional. An MOI of 2.5 therefore provides 2.5 plaque forming units per cell and 
therefore the Poisson distribution says that 92% of cells should be infected by at least 
one viral particle.  
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Figure 4. Genetic Structure of Relevant Viruses 
Viruses were originally created using the HSVQuik method as described previously23. Viruses are 
rendered tumor specific by deleting both γ34.5 copies as well as interfering with ICP6/RR by 
inserting the genes for GFP and, in the case of rQ1-α-Fluc, the luciferase transgene. The 
luciferase transgene was inserted under an IE4/5 promoter, as this was previously determined 
provide optimal luciferase visualization23.  
F-Strain and rHSVQ1 adapted from Hardcastle et. al. Molecular Therapy 2010. 18(2). Q1- α-Fluc 
graphic was created using his framework. 
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Luciferase and the BCA Assay 
 The Luciferase assay determines the concentration of luciferase transgenetic 
enzyme by measuring luminescence. Cells were lysed in 1X Cell Lysis Buffer (Promega 
Corp., Madison, WI ) after a wash in Dulbecco’s Phosphate Buffered Saline 
(Invitrogen). A cell scraper was used to collect the lysate, which was then vortexed, 
centrifuged to remove cellular debris, and supernatant was frozen. Luciferase activity 
was measured using the Luciferase Assay System (Promega Corp, Madison, WI). After 
washing and priming the machine, 80 µL luciferase reagent was automatically added 
to each 20 µL sample. Luminescence was determined using a Fluorstar Optima reader 
with negative controls to account for background. 
 Protein concentration was controlled for using the bicinchoninic acid protein 
assay (BCA assay).  The BCA assay is dependent upon copper ion reduction to 
produce a colorimetric change. The Pierce® Microplate BCA Protein Assay Kit – 
Reducing Agent Compatible (Thermo Scientific) was used according to 
manufacturer’s protocol and working reconstitution buffer was not diluted. Protein 
concentrations were determined by plotting absorbance against a four-parameter 
quadratic curve. This was created by the FLuostar Optima program by subtracting 
average absorbance of a blank of 1X Cell Lysis Buffer and finding the best fit line for 
serially diluted known quantities of BSA. Measurements were taken at 562 nm. 
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Western Blots 
 Immunoblots were performed on cell lysates from indicated cells. Cells were 
was washed in DPBS and lysed for Western blot in RIPA buffer: 0.1% SDS, 150mM 
Tris, 150mM NaCl, 1% Nonidet P-40, 0.5% sodium Deoxycholate. If specifically noted, 
cells were lysed in 1X Cell Lysis Buffer. A cell scraper was used to collect all lysates. 
20µL sample was added to 10 µL SDS buffer with 4% 2-mercaptoethanol. After 
vortexing and centrifugation, samples were heated to 100˚C for 5 minutes, and then 
samples were vortexed and centrifuged again. Cyr61 protein gels were resolved on 
10% SDS-PAGE, and IFITM3 gels were run on a 4-20% SDS-PAGE. 
 Protein was transferred to PVDF membranes and blocked for at least an hour 
in blocking buffer (5% non-fat dry milk (LabScientific Inc.) in 0.1% Tween and 1X 
Phosphate Buffered Saline (PBS-T)) to inhibit non-specific binding between the 
membrane and nonspecific antibodies. Membranes were incubated in primary 
antibody for an hour and washed 3x 5 min in PBS-T to remove unbound and 
nonspecifically bound antibodies. Secondary antibody incubations were 1 hour and 
were followed by 3x10 min washes in PBS-T and 1x5 min wash in 1xPBS. Visualization 
was accomplished using enhanced chemiluminescence reagents (GE Healthcare, 
Pittsburgh, PA), incubated 5 min per manufacturer’s protocol. Bands were visualized 
after exposure and development on hyBlot CL autoradiography film (Dennville 
Scientific Inc., Metuchen, NJ). 
 All antibodies were diluted in blocking buffer. Cyr61 antibody (Novus 
Biologicals) was diluted 1:750 and a goat anti-rabbit HRP (Dako) diluted at 1:1000 was 
24 
 
used as a secondary. IFITM3 antibody (Abgent) was diluted 1:200 and the anti-rabbit 
HRP was again used as a secondary antibody. To control for protein levels, blots were 
probed for GAPDH, a gene constitutively expressed at high levels and frequently used 
as a loading control. The GAPDH antibody (Abcam) was diluted 1:5,000. The 
secondary sheep anti-mouse HRP (GE Healthcare) was incubated 1:10,000. 
RNA Preparation and Semi-quantitative Real-time PCR 
 Cells were harvested with 0.5% trypsin-EDTA, centrifuged to remove cellular 
debris and the cell pellets were then frozen. Homogenization was accomplished with 
the QIAshredder (Qiagen) and RNA was isolated using an RNeasy Mini Kit (Qiagen). 
The Titan One Tube RT PCR System (Roche) was used for semi-quantification per 
manager’s protocol. GAPDH was used as an internal control with relative 
quantification being expressed as a ratio of the difference in the number of cycles 
needed for detection at a certain level. Primers were designed using the Primer 
Express Program (Applied Biosystems). 
Microarray. 
 Clone 16 cells were incubated with doxycycline for 24 h and harvested using 
0.5% Trypsin-EDTA. After centrifugation, RNA was isolated as mentioned previously. 
Samples, in triplicate, were then submitted to The Ohio State University Microarray 
Shared Resource Center for microarray analysis using the Affymetrix GeneChip 
Analysis and analyzed by an affiliated statistician. 
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Transfections and Cloning 
 To create Cy-1, the open reading frame of Cyr61 (amino acids 1-382) was 
cloned into pcDNA 3.1+myc-His (Invitrogen) for constitutive expression (wt Cyr61) or 
into pTRE2 (Clontech) for tetracycline-regulated expression (Cyr61mycHisTRE2) using 
standard techniques. Transient transfections involving IFITM3 were performed using 
Lipofectamine 2000 (Invitrogen) per protocol from manufacturer. Transient 
transfections involving Cyr61 were carried out using Lipofectamine reagent and Plus 
Reagent (Invitrogen) per manufacturer’s protocol.  
Animals 
 All animal experiments were performed in accordance with the Subcommittee 
on Research Animal Care of the Ohio State University guidelines. Athymic nude mice 
6-8 weeks of age were purchased from NCI/NIH. To create subcutaneous tumors, 
mice were anesthetized and injected in the rear right flank with 4x106 Cy-1 cells. 
Measurement the tumor were taken using digital calipers and used the ellipsoid 
volume formula ½xLxW2, where the shortest dimension was used as the width(24). The 
use of W2 was necessary due to the difficulties inherent when measuring height of a 
tumor within a living mouse.  When subcutaneous tumors reached 2,000 mm3 or per 
protocol, mice were sacrificed and tumors were collected for analysis. 
Statistical Analysis 
 Results are presented as mean values ±  standard errors of the mean. 
Statistical analysis was carried out using Students’ t-test using Excel 2007. P values of 
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<0.05 were considered statistically significant. Affymetrix GeneChip was used for 
gene expression study. Signal intensities were quantified by Affymetrix software, and 
background correction and quantile normalization were performed to adjust 
technical biases. Gene expression levels were summarized over probe set using the 
RMA method, and a filtering method based on percentage of arrays above noise 
cutoff was applied to filter out low expression genes. A linear model was used to 
detect differential expression of genes. To improve estimates of variability and 
statistical tests for gene expressions, a variance shrinkage method was employed, 
and the significance level was adjusted by controlling the mean number of false 
positives. 
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Chapter 3: Results 
Created Tetracycline-on Cell Lines Demonstrate Cyr61 Induction Upon 
Doxycycline Treatment 
 Transient transfections of Cyr61 have been shown to inhibit OV infection  
(Haseley at al, Unpublished). To validate this we created an inducible cell line. In 
order to create such a cell line, LN229 was stably transfected with an rtTA expression 
vector using Lipofectamine and Plus reagent per manufacturer’s protocol. This rtTA 
expression vector, known as Tet-On, is activated by the presence of doxycycline and 
offers benefits over other modalities of activation. Tet-on is less leaky than the 
estrogen receptor and is reversible, unlike the Cre and FRT systems. After isolating a 
Tet-responsive clone, cells were transfected with Cyr61mycHispTRE2 and selected for 
neomycin resistance (900µg/mL) and tested for Cyr61 induction following doxycycline 
treatment (1 µg/mL for 24 hrs). Expression of Cyr61 RNA following transfection was 
determined using a Titan One Tube RT-PCR kit, as previously described. As is seen in 
Figure 5, treatment with doxycycline (Dox) leads to the expression of Cyr61 in Cy-1 at 
all examined time points. Having created and verified the Tet-On model, experiments 
independent of transfection could be performed. 
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Figure 5. Cyr61 Induced by Doxycycline at Various Time Points. 
Cy-1 cells were treated with Doxycycline at 1 µg/mL and harvested at various timepoints. GAPDH is 
used as a loading control. Cy-1 overexpresses Myc-tagged Cyr61 upon doxycycline (dox) treatment 
from 4 to 72 hours after treatment. 
+ - + - + - + -            + - + - + - + -              
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In Vitro Inhibition of OV infection in Dox Model 
 With the Tet-On model now available for use, the verification of inhibition 
was of particular interest. Cy-1 cells were treated with Dox for 24 hours. Cells were 
infected with rHSVQ1 at a Multiplicity of Infection (MOI) of 2.5 for two hours, and 
then washed twice with PBS. The high MOI should ensure that almost every cell is 
infected, as an average of 92% of cells will be infected with at least one viral particle, 
although this number might be diminished very slightly by the PBS washes. The PBS 
wash serves to remove any extraneous viral particles still floating, and ensures that 
the later viral particle count only comes from infected cells. Therefore, all viral 
particles assayed should be progeny of the first round of infection. 24 hours later, 
cells were harvested for viral particle titer. 
 After freeze-thaw cycles, which disrupt the cell and release the viral particles 
without destroying them, the virus was collected and centrifuged to remove cellular 
debris. Supernatants were then used to infect Vero cells for 24 hours and viral 
progeny was determined using viral titration, as described in the methods. As Figure 
6 demonstrates, fewer functional viral particles are produced upon dox treatment. 
This confirms the inhibiton previously seen following transient transfections. 
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Figure 6. Tetracycline-Induced Cyr61 Inhibits OV Propagation. 
Cy-1 tet-inducible cells were treated with and without doxycycline (dox) and infected. After 24 
hours, virus was collected and the number of viral particles was determined using viral 
titration as seen in the methods. Cyr61 upregulation, induced by doxycycline treatment, 
decreased viral progeny. 
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Characterization of Dox Model 
 Having confirmed Cyr61 mediated inhibition, it was important to characterize 
Cy-1. Conditional expression of Cyr61 in a glioma cell line is novel, and pathways of 
Cyr61 mediated inhibition of viral infection have not previously been described. Two 
studies were of particular interest and relevance. First, cells were treated with 
doxycycline or with normal media.  They were then harvested every day for 4 days by 
fixing with gluteradehyde, and stained with crystal violet. Crystal violet binds to DNA, 
and thus offers a consistent method of visualization and quantification of cell growth. 
Quantification was performed using absorbance at OD595 and a significant difference 
was noted between doxycycline treated and untreated cells, as is shown by Figure 7. 
Cyr61 upregulation also slowed cellular growth.  
 Cy-1 characterization was also performed in vivo. Mice were implanted with 
subcutaneous tumors and treated with doxycycline. Dox stock solution was filtered at 
0.22µm and diluted to 1mg/mL in sucrose water (5%), as mice resist drinking water 
with doxycycline if unsweetened. As Figure 8 demonstrates, the growth rate of the 
tumors was significantly diminished. 
   
32 
 
 
 
  
Figure 7. In Vitro Oxerexpression of Cyr61 Slows Glioma Cell Growth 
Cy-1 and LN229 cells were treated with and without doxycycline and harvested at different 
time points for cellular density. 
Treatment of Cy-1 cells with doxycycline led to decreased growth, while untreated cells grew 
normally. LN229 was used to ensure that doxycycline itself didn’t inhibit growth, as Cy-1 is 
derived from the transfection of LN229 cells. Dox had no effect upon LN229 growth rates. 
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Figure 8. In Vivo Overexpression of Cyr61 Slows Tumor Growth 
Subcutaneous tumors were created using Cy-1 and mice were treated with doxycycline after 
tumors reached 100 mm3 and growth was measured weekly. As is seen, doxycycline treated mice 
showed decreased tumor growth. Western blots of tumor lysates show sustained Cyr61 
upregulation with dox treatment. 
       Cy-1 
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IFITM3 Upregulation Shown by Semi-quantitative RT-PCR and Microarray  
 Having confirmed that Cyr61 inhibits infection using multiple modalities and 
to identify the mechanism behind infection, we performed a microarray on Cy-1 cells 
treated with and without doxycycline, as described in previously. IFITM3 was selected 
as a candidate for further study, due to its recently discovered role in defense against 
enveloped viruses (p=2.9x10-9) and due to the high level of its induction. As seen in 
Figure 9, IFITM3 expression was significantly increased following induction of Cyr61. 
This prompted the further review of IFITM3 by semi-quantitative Titan One Tube 
Assay. Cells were transfected with Cyr61, to see if Cyr61 transfection, in addition to 
doxycycline treatment, is able to induce IFITM3. Cells were then harvested as 
discussed previously and the amount of DNA after RT-PCR was qualitatively assessed. 
In addition, semi-quantitative measurement of the bands was undertaken. As seen in 
Figure 10, IFITM3 was clearly upregulated following transfection with Cyr61. 
 This observation strengthened the status of IFITM3 as a candidate gene and 
prompted a full investigation. If IFITM3 was discovered to mediate Cyr61 induced 
inhibition of OV infection, this would provide two novel results. First, Cyr61’s 
mechanism of OV inhibition has not been previously described. Secondly, IFITM3’s 
role in either OV therapy or with HSV1 was not previously been examined. 
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Figure 9. IFITM3 Levels Higher after Dox Treatment of Cy-1.  
Cy-1 Cells treated with and without doxycycline were subjected to a microarray. The data, 
after statistical analysis, was in the format of Control/Sample, and thus the number below 1 
demonstrates a higher level of IFITM3 in dox treated cells. 
 IFITM3 was selected as a candidate due to the high significance of increased IFITM3 levels in 
doxycycline treated cells when compared to untreated cells (p= 2.9x10-9). This suggested that 
Cyr61 upregulates IFITM3. 
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Figure 10. Titan Semi-quantification RT-PCR Confirms IFITM3 Upregulation 
Following Cyr61 Transfection. 
U251T2 cells were transfected with Cyr61 and harvested for semi-quantification of IFITM3 
RNA levels. After taking into account the loading control, IFITM3 is shown to be upregulated. 
Above are original bands, and below is quantification of band strength. IFITM3 is shown to be 
upregulated following Cyr61 transfection (p=0.0059). 
37 
 
Western Blot of Multiple Cell Lines Shows IFITM3 Upregulation Following OV 
Infection 
 Cyr61 induction was sufficient to induce IFITM3 gene expression. Next we 
investigated whether IFITM3 was induced in glioma cells upon OV infection. To assess 
this, U87, LN229, Clone 16, U251T2, Gli36 and U343 cell lines were tested to see if 
IFITM3 was induced after rHSVQ1 infection. 1x105 cells of each cell line besides U87 
were plated on a 12 well plate. U87 only had 8x104 cells plated, due to its tendency 
towards cells forming balls at higher confluencies. The next day, cells were infected at 
an MOI of 0.1 and untreated samples were harvested. The harvested cells were lysed 
and analyzed 24 hours after infection by Western blot to check for expression of 
IFITM3 relative to cellular GAPDH protein levels. Gli36 and Cy-1 showed IFITM3 
upregulation subsequent to OV infection. Interestingly, this induction was not 
observed in U343 or U251T2, as seen in Figure 11. This could be due to issues with 
sensitivity from the low MOI used. Only 10% of cells are initially infected, but 
subsequent infection cycles would be expected to infect the majority of cells. The low 
MOI is used intentionally, as higher MOIs might flood the cells with viral particles, 
whose numbers might infect many more cells, masking any inhibitory effect.   
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Figure 11. Western Blot Shows Effects of OV Infection in Different Cell 
Lines. 
Cells were harvested before and 24 hours after rHSVQ1 infection. Gli36, Cy-1 and 
U87 show IFITM3 upregulation following infection.  
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No Inhibition Shown By Luciferase Following IFITM3 Transient Transfection 
 The luciferase expressing rQ1-α-Fluc provides an ideal model for examining 
viral levels following OV infection. As the luciferase transgene is under an immediate-
early promoter, cells should produce luciferase very soon after infection and thus 
luciferase is an indirect marker of viral infectivity. 3x105 cells of LN229 and U87 were 
transfected with 2µg DNA per well. As Figure 12 demonstrates, no significant 
difference in infection was observed in LN229 (p=0.20) or U87 (p=0.40), even with 
clear upregulation of IFITM3. Having observed no significant difference in OV 
infection in any cell line, it was deemed unlikely that IFITM3 mediates OV inhibition.  
 However, one further critique might be raised. It could be that exposure to 
OVs leads to IFITM3 induction and this increase “masks” the effect of the 
transfection. All samples for the Western blots verifying transfection were harvested 
at the time of infection. This is because high IFITM3 levels at the start of infection 
were desirable to demonstrate that IFITM3 was present to inhibit the virus. To 
preempt this criticism, the samples harvested for luciferase examination in 1x Cell 
Lysis Buffer were assessed by Western blot. As is seen in Figure 13, IFITM3 levels 24 
hours after infection were similar to those seen at the time of infection. That is, 
IFITM3 was present in high levels in the transfected cells and at low levels in the 
control cells. As IFITM3 is minimally present in control cells both at the time of 
infection and at the time of harvesting, induced IFITM3 was determined to not mask 
the transfected IFITM3. These results therefore indicate that IFITM3 is not involved in 
the Cyr61 mediated inhibition of OV therapy in vivo. 
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Figure 12. No Difference in Infection following IFITM3 upregulation in LN229 
and U87. 
As U251T2 showed no significant difference in infection, U87 and LN229 were analyzed. 
Following transfection with the IFITM3 plasmid and infection, LN229 (p=0.20) and U87 
(p=0.40) showed no significant difference in infection. As the Western blots show, IFITM3 
is present at high levels in the IFITM3 transfected cells but not in the control transfected 
cells. 
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Figure 13. Transfected Cells Still Express IFITM3 24 Hours After Infection. 
Samples harvested in 1x Cell Lysis Buffer and used for luciferase examination were tested 
by Western Blot. Cells transfected with IFITM3 and showing no OV inhibition still 
demonstrate IFITM3 upregulation at the time of harvesting 24 hours after initial 
infection, and 48 hours after initial transfection. 
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Chapter 4: Discussion and Conclusion 
 OV therapy offers great potential for treating currently incurable cancers, but 
problems such as the innate defenses against viruses limit clinical application. Here, 
we have built upon the known induction of Cyr61 and identified, for the first time, 
that Cyr61 upregulation inhibits OV therapy using transient transfections. A 
tetracycline inducible model was then created to test inhibition. All modalities 
confirmed that Cyr61 inhibits OV therapy.  
 Inhibition obviously limits treatment efficacy, and thus methods aiming to 
prevent upregulation might improve therapy. One might consider including DNA for 
the knockdown Cyr61 in infected cells. However, many shRNAs, siRNAs and one 
shRNA containing virus were all been unable to knockdown Cyr61, so the effort was 
abandoned (data unpublished). With the most apparent target proving difficult, 
greater emphasis was put on identifying the mechanism of inhibition. 
Characterization of tetracycline-inducible clones suggested that the innate antiviral 
response might be activated by Cyr61. 
 A microarray and mRNA panel identified that IFITM3 was upregulated when 
Cyr61 was upregulated. IFITM3 was thus identified as a potential mediator of 
inhibition, due to its known inhibition of some enveloped viruses, and selected for 
further evaluation. The evaluation of multiple cell lines demonstrated that OV 
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infection could induce IFITM3 production, thus providing the possibility that IFITM3 
does mediate the observed inhibition. However, upregulation of IFITM3 by transient 
transfection proved to have no effect upon infection in vitro. This proves the 
hypothesis that IFITM3 mediates the in vitro observed OV inhibition following Cyr61 
upregulation false. 
 Thus, agents inhibiting IFITM3 are not potential candidates for an adjunct to 
OV therapy. Ongoing studies aim to identify and understand the mechanisms behind 
Cyr61 instigated OV inhibition. If identified, this could provide two benefits. First, 
further analysis of innate immune mechanisms could provide therapeutic targets for 
more specific immune response modulation with fewer side effects. Secondly, by 
blocking the identified pathway, the efficacy of OV therapy might be improved. 
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